The suggested role of Hsp60, as a common target to address the two pathologies, opens up a new field of pharmacological interventions and/or a potential repositioning of drugs already used for Type 2 Diabetes Mellitus in Alzheimer’s disease, which, to date, is without a resolutive cure. This evidence concerns the gene HSPD1 and diabetes mellitus.